Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trafficking kinesin-binding protein 2 (TRAK2) is a cytoplasmic adaptor protein that links mitochondria and possibly other cargoes to microtubule-based motors, especially kinesin-1 and dynein. TRAK2 facilitates the bidirectional transport of mitochondria along microtubules by coordinating and activating kinesin-1 for plus-end (anterograde) movement and dynein-dynactin for minus-end (retrograde) movement. The protein plays a particularly prominent role in mitochondrial trafficking in dendrites, is involved in GABA receptor binding, and is associated with diseases such as juvenile amyotrophic lateral sclerosis. TRAK2 does not appear to be a direct therapeutic target such as a receptor or enzyme but functions as an important regulatory component in neuronal transport systems[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trafficking kinesin-binding protein 2 (TRAK2).